
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Harmony Biosciences Holdings (HRMY)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: HRMY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $50.55
1 Year Target Price $50.55
5 | Strong Buy |
3 | Buy |
0 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.62% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.10B USD | Price to earnings Ratio 11.78 | 1Y Target Price 50.55 |
Price to earnings Ratio 11.78 | 1Y Target Price 50.55 | ||
Volume (30-day avg) 9 | Beta 0.84 | 52 Weeks Range 26.47 - 41.61 | Updated Date 08/15/2025 |
52 Weeks Range 26.47 - 41.61 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.72 | Actual 0.92 |
Profitability
Profit Margin 23.42% | Operating Margin (TTM) 24.03% |
Management Effectiveness
Return on Assets (TTM) 14.1% | Return on Equity (TTM) 27.58% |
Valuation
Trailing PE 11.78 | Forward PE 10.26 | Enterprise Value 1707336262 | Price to Sales(TTM) 2.72 |
Enterprise Value 1707336262 | Price to Sales(TTM) 2.72 | ||
Enterprise Value to Revenue 2.21 | Enterprise Value to EBITDA 6.44 | Shares Outstanding 57532600 | Shares Floating 44565903 |
Shares Outstanding 57532600 | Shares Floating 44565903 | ||
Percent Insiders 11.07 | Percent Institutions 97.34 |
Upturn AI SWOT
Harmony Biosciences Holdings

Company Overview
History and Background
Harmony Biosciences Holdings, Inc. was founded in 2017. The company focuses on developing and commercializing therapies for rare neurological diseases, with a commitment to addressing unmet medical needs.
Core Business Areas
- Rare Neurological Diseases: Focuses on the development and commercialization of therapies for patients living with rare neurological diseases, particularly those affecting sleep and wakefulness.
Leadership and Structure
Harmony Biosciences is led by a management team with experience in the pharmaceutical industry. The organizational structure comprises various departments including research and development, commercial operations, medical affairs, and finance.
Top Products and Market Share
Key Offerings
- Wakix (pitolisant): Wakix is a first-in-class histamine-3 (H3) receptor antagonist/inverse agonist approved for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. It holds a significant market share in this segment. Competitors include Xyrem, Xywav and Sunosi.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the rare disease segment, is experiencing growth driven by increasing awareness, advancements in diagnostics, and regulatory support for orphan drugs.
Positioning
Harmony Biosciences has positioned itself as a leader in developing and commercializing therapies for narcolepsy and other rare neurological diseases. Its competitive advantage lies in its focus on novel mechanisms of action and unmet medical needs.
Total Addressable Market (TAM)
The narcolepsy market is estimated to be in the billions of USD. Harmony is positioned to expand in this market through drug development and approval.
Upturn SWOT Analysis
Strengths
- Novel treatment options
- Strong commercial performance of Wakix
- Experienced management team
- Focus on rare neurological diseases
Weaknesses
- Reliance on a limited product portfolio
- Competition from established players
- Regulatory risks associated with drug development
- Lack of a diverse portfolio
Opportunities
- Expansion into new indications
- Strategic acquisitions and partnerships
- Geographic expansion
- Further clinical development of pipeline candidates
Threats
- Generic competition
- Pricing pressures
- Changes in healthcare regulations
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JAZZ
- AVXL
- SNDL
Competitive Landscape
Harmony Biosciences competes with other pharmaceutical companies in the narcolepsy market. The company's advantages include its novel mechanism of action with Wakix, while disadvantages include its reliance on a limited product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical performance data needs to be pulled from a live financial terminal at the time of request. This will be available from the next model version.
Future Projections: Future Projections data needs to be pulled from a live financial terminal at the time of request. This will be available from the next model version.
Recent Initiatives: Harmony's recent initiatives include expanding the label for Wakix and pipeline advancement.
Summary
Harmony Biosciences is a pharmaceutical company with a focus on rare neurological diseases. Wakix sales continue to grow, establishing their presence in the narcolepsy market. Future growth depends on pipeline development and competition in an established market will provide challenges. They must look out for potential generic competition and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary. Actual financial results may differ.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harmony Biosciences Holdings
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 2020-08-19 | President, CEO & Director Dr. Jeffrey M. Dayno M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 268 | |
Full time employees 268 |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.